Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Aug 25;20(10):80.
doi: 10.1007/s11912-018-0729-3.

The Role of Oncolytic Viruses in the Treatment of Melanoma

Claire-Audrey Y Bayan  1 , Adriana T Lopez  1 , Robyn D Gartrell  2 , Kimberly M Komatsubara  2 , Margaret Bogardus  1 , Nisha Rao  2 , Cynthia Chen  1 , Thomas D Hart  3 , Thomas Enzler  2 , Emanuelle M Rizk  2 , Jaya Sarin Pradhan  4 , Douglas K Marks  2 , Larisa J Geskin  5 , Yvonne M Saenger  6
Affiliations
Review

The Role of Oncolytic Viruses in the Treatment of Melanoma

Claire-Audrey Y Bayan et al. Curr Oncol Rep. .

Erratum in

Abstract

Purpose of review: Oncolytic virotherapy is a new approach to the treatment of cancer and its success in the treatment of melanoma represents a breakthrough in cancer therapeutics. This paper provides a review of the current literature on the use of oncolytic viruses (OVs) in the treatment of melanoma.

Recent findings: Talimogene laherparepvec (T-VEC) is the first OV approved for the treatment of melanoma and presents new challenges as it enters the clinical setting. Several other OVs are at various stages of clinical and pre-clinical development for the treatment of melanoma. Reports from phase Ib-III clinical trials combining T-VEC with checkpoint blockade are encouraging and demonstrate potential added benefit of combination immunotherapy. OVs have recently emerged as a standard treatment option for patients with advanced melanoma. Several OVs and therapeutic combinations are in development. Immunooncolytic virotherapy combined with immune checkpoint inhibitors is promising for the treatment of advanced melanoma.

Keywords: Biosafety; Combination therapy; Immunotherapy; Melanoma; Oncolytic viral therapy; Oncolytic virus; Talimogene laherparepvec (T-VEC); Tumor microenvironment.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: none

References

    1. Fountzilas C, Patel S, Mahalingam D. Review: Oncolytic virotherapy, updates and future directions. Oncotarget. 2017;8(60):102617–39. - PMC - PubMed
    1. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science. 1991;252(5007):854–6. - PubMed
    1. Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14(9):642–62. - PMC - PubMed
    1. Maroun J, Munoz-Alia M, Ammayappan A, Schulze A, Peng KW, Russell S. Designing and building oncolytic viruses. Future Virol. 2017;12(4):193–213. - PMC - PubMed
    1. Yu Z, Chan MK, Oc P, Eisenberg DP, Shah JP, Singh B, et al. Enhanced nectin-1 expression and herpes oncolytic sensitivity in highly migratory and invasive carcinoma. Clin Cancer Res. 2005;11(13):4889–97. - PubMed